KeyBanc last night initiated coverage of Hims & Hers with a Sector Weight rating and no price target The firm views Hims as a “disruptive” direct-to-consumer healthcare business. It is “intrigued” by the company’s international ramp and expansion into more treatments, but believes it may lead to “more muted” margin expansion in 2026. KeyBanc’s fair value estimate is $52 per share.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS: